Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by xiaolu xiong
The Efficacy and Safety of Pemetrexed-Based Doublet Therapy Compared to Pemetrexed Alone for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Updated Meta-Analysis
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Related publications
CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-94 Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Oncologist
Cancer Research
Medicine
Oncology
Pemetrexed Versus Vinorelbine Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Elderly Patients
Molecular and Clinical Oncology
Cancer Research
Oncology
Role of Pemetrexed in Advanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, With Histology Subgroup Analysis
Current Oncology
Oncology
Pemetrexed as Indispensable Drug for the Treatment of Non-Squamous Non-Small Cell Lung Cancer; The Role in Induction and Maintenance Therapy
Cancer Cell & Microenvironment
P1.15-36 a Better Real World Practice for Pemetrexed in First-Line Treatment of Advanced Mon-Squamous Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared With Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer
PLoS ONE
Multidisciplinary
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
